Be part of the 11th Annual BioHealth Capital Region Forum, September 23–24, 2025, at US Pharmacopeia in Rockville, MD. This year’s theme, Where Human and Artificial Intelligence Converge in the BioHealth Industry, will explore groundbreaking advances shaping the future of healthcare. Connect with industry leaders, investors, government, and academia, and gain insights you can apply to your own organization. Attendance is free thanks to our sponsors, but space is limited — secure your spot today

COLUMBIA, Md., (August 28, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced the first three awardees of the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Matching Funds (Matching Funds) program.

“The SBIR/STTR programs, also referred to as America’s Seed Fund, were designed to provide non-dilutive funding that will support a company’s path towards commercialization,” said...

Charlottesville, VA – August 22, 2025 – Luminoah Inc., a medical technology company transforming chronic disease care through personalized enteral nutrition delivery, was selected as the winner of the Startup World Cup Virginia Regional Finals. Out of ten leading startups from across Virginia, Luminoah earned the top spot and will advance to the Grand Finale in San Francisco in October and compete for a $1 million investment prize.

FYI - Finalists for the 2025 Crab Trap Competition will be announced next week!

For the third consecutive year, the BioHealth Capital Region (BHCR), encompassing Maryland, Virginia, and Washington, D.C., has earned a Top 3 position in the highly regarded “Top 10 U.S. Biopharma Clusters” list by Genetic Engineering & Biotechnology News (GEN).

Rich Bendis, CEO and founder of BioHealth Innovation, discusses how the BioHealth Capital Region has grown into a leading US life sciences hub by connecting Maryland, Washington, D.C., and Northern Virginia through a regional, collaborative approach. From supporting early-stage companies with non-dilutive funding and...

Theradaptive, Inc., a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, today announced that the first patient has been successfully treated in the RESTORE International Phase I/II Feasibility Study. This prospective, blinded, randomized, controlled study is designed to evaluate the safety and performance of OsteoAdapt™ DE, a next-generation regenerative product developed to promote bone growth in alveolar ridge augmentation, a surgical dental reconstruction procedure.

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization.

Enjoy live music by The Impurities at the Wednesday evening reception on September 24 at USP. The band features USP team members showcasing their talent outside the lab, including Ron Piervincenzi, Ph.D., CEO, on guitar, Scott Bolgiano on guitar and backing vocals, John Daly on drums, Tim Greiner on lead vocals and harmonica, Alyssa Lang on vocals and saxophone, and Horacio Pappa on keyboards. It is a fun way to connect with peers after a full day of sessions.— register today for the Forum:

Eric Risser has big shoes to fill at MacroGenics Inc.

The Rockville cancer therapy company’s newly minted CEO has just succeeded co-founder and longtime head Scott Koenig, a physician by training, MedImmune alum and National Institutes of Health researcher who’s occupied its top slot for 24 years

But Risser, most recently MacroGenics’ chief operating officer, was involved for 16 of those years, and says he knows what he needs to do..

GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026 Formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

VLP Therapeutics, Inc. (VLPT), Maryland, US-based biotech company, announced on August 27 the initiation of a Phase 1 clinical trial of VLPONC-01, a new cancer immunotherapy, in collaboration with Stanford Medicine. The trial (NCT06736379) is being conducted at Stanford Health Care with the primary objectives of assessing the safety of cancer immunotherapy and identifying the appropriate dosage range for this novel immunotherapy.

Zephyr AI, Inc. (“Zephyr AI”), a leader in precision medicine harnessing artificial intelligence to accelerate drug development, today announced that it has appointed Allen Chao, PhD, as its Chief Executive Officer, and acquired Aster Insights, a premier provider of scientific and clinical intelligence for oncology discovery.

Viva White Oak is a $2.8 billion mixed-use development planned for East Montgomery County. Approved for more than 12 million square feet of mixed-used development, the project will include over 3 million square feet of lab, office, and medical office space, as well as retail and up to 5,000 residences. The site sits adjacent to the U.S. Food and Drug Administration headquarters and near Adventist HealthCare White Oak Medical Center. Viva White Oak also represents the county’s first use of a Tax Increment Financing (TIF) proposal to support development. 

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo.